Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 46Lung Neoplasms 19Melanoma 18Neoplasm Metastasis 16Carcinoma, Hepatocellular 15Neoplasms 13Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Colorectal Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Stomach Neoplasms 6Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Renal Cell 6Brain Neoplasms 6Small Cell Lung Carcinoma 5Recurrence 5Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Liver Neoplasms 4Glioblastoma 4Cholangiocarcinoma 4Prostatic Neoplasms 3Nasopharyngeal Carcinoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced Non-small Cell Lung Cancer × Immunotherapy × Clear all
NCT06287320 2024-03-01

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown
200 enrolled
Thoracic

Locally Advanced Non-small Cell Lung Cancer

NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡